{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,13]],"date-time":"2026-05-13T09:09:26Z","timestamp":1778663366156,"version":"3.51.4"},"reference-count":40,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,4,2]],"date-time":"2026-04-02T00:00:00Z","timestamp":1775088000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,5,13]],"date-time":"2026-05-13T00:00:00Z","timestamp":1778630400000},"content-version":"vor","delay-in-days":41,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"Department of Biostatistics and Data Science at the University of Texas Medical Branch"},{"name":"Sealy and Smith Foundation, United States"},{"DOI":"10.13039\/100006108","name":"National Center for Advancing Translational Sciences","doi-asserted-by":"publisher","award":["1UM1TR005443"],"award-info":[{"award-number":["1UM1TR005443"]}],"id":[{"id":"10.13039\/100006108","id-type":"DOI","asserted-by":"publisher"}]},{"name":"the Chauncey Leake Distinguished Professor Endowment"},{"name":"the Center for Addiction Sciences and Therapeutics (CAST) at the University of Texas Medical Branch"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Harm Reduct J"],"DOI":"10.1186\/s12954-026-01441-x","type":"journal-article","created":{"date-parts":[[2026,4,2]],"date-time":"2026-04-02T12:38:04Z","timestamp":1775133484000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Pharmacy-level barriers to opioid overdose prevention: availability and accessibility of naloxone and buprenorphine\u2013naloxone in high-risk Texas counties"],"prefix":"10.1186","volume":"23","author":[{"given":"Kyce G.","family":"Darouiche","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Moosa M.","family":"Malik","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maegan T.","family":"Mohr","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michelle A.","family":"Hagenimana","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Biai D. E.","family":"Digbeu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kathryn A.","family":"Cunningham","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"N. Miles","family":"Farr","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carlos R.","family":"Dostal","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2026,4,2]]},"reference":[{"issue":"6","key":"1441_CR1","doi-asserted-by":"publisher","first-page":"202","DOI":"10.15585\/MMWR.MM7006A4","volume":"70","author":"CL Mattson","year":"2021","unstructured":"Mattson CL, Tanz LJ, Quinn K, Kariisa M, Patel P, Davis NL. Trends and geographic patterns in drug and synthetic opioid overdose deaths - United States, 2013-2019. MMWR Morb Mortal Wkly Rep. 2021;70(6):202\u20137. https:\/\/doi.org\/10.15585\/MMWR.MM7006A4.","journal-title":"MMWR Morb Mortal Wkly Rep"},{"issue":"10","key":"1441_CR2","doi-asserted-by":"publisher","first-page":"1081","DOI":"10.2105\/AJPH.2024.307745","volume":"114","author":"A Nguyen","year":"2024","unstructured":"Nguyen A, Wang J, Holland KM, et al. Trends in drug overdose deaths by intent and drug categories, United States, 1999\u20122022. Am J Public Health. 2024;114(10):1081\u20135. https:\/\/doi.org\/10.2105\/AJPH.2024.307745.","journal-title":"Am J Public Health"},{"key":"1441_CR3","doi-asserted-by":"publisher","DOI":"10.7759\/CUREUS.79175","author":"EJ Nicanord","year":"2025","unstructured":"Nicanord EJ, Lee WC, Konopnicki SA, Campbell K. Trends in drug and polysubstance-related deaths in the state of Texas: county comparisons. Cureus. 2025. https:\/\/doi.org\/10.7759\/CUREUS.79175.","journal-title":"Cureus"},{"key":"1441_CR4","unstructured":"Texas Health Data - Drug-Related Deaths. https:\/\/healthdata.dshs.texas.gov\/dashboard\/drugs-and-alcohol\/all-drugs\/drug-related-deaths. Accessed 5 Sep 2025"},{"key":"1441_CR5","unstructured":"Texas Overdose Data to Action | Texas DSHS. https:\/\/www.dshs.texas.gov\/injury-prevention\/texas-overdose-data-action#. Accessed 19 Sep 2024"},{"key":"1441_CR6","unstructured":"SUDORS Dashboard: Fatal Drug Overdose Data | Overdose Prevention | CDC. https:\/\/www.cdc.gov\/overdose-prevention\/data-research\/facts-stats\/sudors-dashboard-fatal-overdose-data.html. Accessed 5 Jul 2025"},{"issue":"18","key":"1441_CR7","doi-asserted-by":"publisher","first-page":"1934","DOI":"10.1001\/JAMA.2018.15892","volume":"320","author":"KE Evoy","year":"2018","unstructured":"Evoy KE, Hill LG, Groff L, Mazin L, Carlson CC, Reveles KR. Naloxone accessibility without a prescriber encounter under standing orders at community pharmacy chains in Texas. JAMA. 2018;320(18):1934. https:\/\/doi.org\/10.1001\/JAMA.2018.15892.","journal-title":"JAMA"},{"key":"1441_CR8","unstructured":"FDA Approves First Over-the-Counter Naloxone Nasal Spray | FDA. https:\/\/www.fda.gov\/news-events\/press-announcements\/fda-approves-first-over-counter-naloxone-nasal-spray. Accessed 19 Sep 2024"},{"key":"1441_CR9","doi-asserted-by":"publisher","DOI":"10.1186\/S12954-022-00651-3","author":"D Dadiomov","year":"2022","unstructured":"Dadiomov D, Bolshakova M, Mikhaeilyan M, Trotzky-Sirr R. Buprenorphine and naloxone access in pharmacies within high overdose areas of Los Angeles during the COVID-19 pandemic. Harm Reduct J. 2022. https:\/\/doi.org\/10.1186\/S12954-022-00651-3.","journal-title":"Harm Reduct J"},{"issue":"6","key":"1441_CR10","doi-asserted-by":"publisher","first-page":"1505","DOI":"10.1111\/add.15314","volume":"116","author":"LG Hill","year":"2021","unstructured":"Hill LG, Loera LJ, Evoy KE, et al. Availability of buprenorphine\/naloxone films and naloxone nasal spray in community pharmacies in Texas, USA. Addiction. 2021;116(6):1505\u201311. https:\/\/doi.org\/10.1111\/add.15314.","journal-title":"Addiction"},{"key":"1441_CR11","doi-asserted-by":"publisher","DOI":"10.1016\/j.drugalcdep.2022.109518","author":"LG Hill","year":"2022","unstructured":"Hill LG, Loera LJ, Torrez SB, et al. Availability of buprenorphine\/naloxone films and naloxone nasal spray in community pharmacies in 11 U.S. states. Drug Alcohol Depend. 2022. https:\/\/doi.org\/10.1016\/j.drugalcdep.2022.109518.","journal-title":"Drug Alcohol Depend"},{"key":"1441_CR12","unstructured":"How Available Is Over-the-Counter Naloxone in Houston? | Baker Institute. https:\/\/www.bakerinstitute.org\/research\/how-available-over-counter-naloxone-houston. Accessed 18 Sep 2024"},{"key":"1441_CR13","unstructured":"Medications for Opioid Use Disorder. Medications for opioid use disorder: for healthcare and addiction professionals, policymakers, patients, and families: updated 2021. 2018. https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK574910\/. Accessed 15 Sep 2024"},{"issue":"2Suppl 1","key":"1441_CR14","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1097\/ADM.0000000000000633","volume":"14","author":"C Cunningham","year":"2020","unstructured":"Cunningham C, Edlund MJ, Fishman M, Gordon AJ, Jones HE, Langleben D, et al. The ASAM national practice guideline for the treatment of opioid use disorder: 2020 focused update. J Addict Med. 2020;14(2Suppl 1):1\u201391. https:\/\/doi.org\/10.1097\/ADM.0000000000000633.","journal-title":"J Addict Med"},{"key":"1441_CR15","doi-asserted-by":"publisher","first-page":"892","DOI":"10.1111\/jcpt.13114","volume":"45","author":"JV Pergolizzi Jr","year":"2020","unstructured":"Pergolizzi JV Jr, Raffa RB, Rosenblatt MH, Pergolizzi JCV Jr. Opioid withdrawal symptoms, a consequence of chronic opioid use and opioid use disorder: current understanding and approaches to management. J Clin Pharm Ther. 2020;45:892\u2013903. https:\/\/doi.org\/10.1111\/jcpt.13114.","journal-title":"J Clin Pharm Ther"},{"key":"1441_CR16","doi-asserted-by":"publisher","unstructured":"Santo Jr T, Clark B, Hickman M, et al. Association of opioid agonist treatment with all-cause mortality and specific causes of death among people with opioid dependence a systematic review and meta-analysis supplemental content. 2023. https:\/\/doi.org\/10.1001\/jamapsychiatry.2021.0976.","DOI":"10.1001\/jamapsychiatry.2021.0976"},{"issue":"22","key":"1441_CR17","doi-asserted-by":"publisher","first-page":"2301","DOI":"10.1001\/JAMA.2020.8020","volume":"323","author":"AH Krist","year":"2020","unstructured":"Krist AH, Davidson KW, Mangione CM, et al. Screening for unhealthy drug use: US preventive services task force recommendation statement. JAMA. 2020;323(22):2301\u20139. https:\/\/doi.org\/10.1001\/JAMA.2020.8020.","journal-title":"JAMA"},{"issue":"7","key":"1441_CR18","doi-asserted-by":"publisher","DOI":"10.1001\/JAMANETWORKOPEN.2024.23954","volume":"7","author":"SG Weiner","year":"2024","unstructured":"Weiner SG, Little K, Yoo J, et al. Opioid overdose after medication for opioid use disorder initiation following hospitalization or ED visit. JAMA Netw Open. 2024;7(7):e2423954. https:\/\/doi.org\/10.1001\/JAMANETWORKOPEN.2024.23954.","journal-title":"JAMA Netw Open"},{"key":"1441_CR19","doi-asserted-by":"publisher","DOI":"10.1016\/j.drugalcdep.2021.108729","author":"NJ Kazerouni","year":"2021","unstructured":"Kazerouni NJ, Irwin AN, Levander XA, et al. Pharmacy-related buprenorphine access barriers: an audit of pharmacies in counties with a high opioid overdose burden. Drug Alcohol Depend. 2021. https:\/\/doi.org\/10.1016\/j.drugalcdep.2021.108729.","journal-title":"Drug Alcohol Depend"},{"key":"1441_CR20","doi-asserted-by":"publisher","DOI":"10.1016\/j.rcsop.2023.100356","author":"BA DiPaula","year":"2023","unstructured":"DiPaula BA, Cooke CE. Assessing Suboxone access in community pharmacies: secret shopper model. Explor Res Clin Soc Pharm. 2023. https:\/\/doi.org\/10.1016\/j.rcsop.2023.100356.","journal-title":"Explor Res Clin Soc Pharm"},{"issue":"5","key":"1441_CR21","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.15123","volume":"13","author":"J Pergolizzi","year":"2021","unstructured":"Pergolizzi J, LeQuang JAK, Breve F. The end of the X-Waiver: not a moment too soon! Cureus. 2021;13(5):e15123. https:\/\/doi.org\/10.7759\/cureus.15123.","journal-title":"Cureus"},{"key":"1441_CR22","unstructured":"Texas Health Data - Drug-Related Deaths. https:\/\/healthdata.dshs.texas.gov\/dashboard\/drugs-and-alcohol\/drug-related-deaths. Accessed 19 Sep 2024"},{"key":"1441_CR23","unstructured":"Executive Office of the President. 2023. https:\/\/www.whitehouse.gov\/omb\/information-for-agencies\/bulletins\/. Accessed 21 Feb 2026."},{"key":"1441_CR24","unstructured":"Bureau UC. Metropolitan and Micropolitan. https:\/\/www.census.gov\/programs-surveys\/metro-micro.html. Accessed 21 Feb 2026"},{"key":"1441_CR25","unstructured":"TSBP Website - Texas State Board of Pharmacy. https:\/\/www.pharmacy.texas.gov\/dbsearch\/phy_search.asp. Accessed 4 Sep 2025"},{"issue":"2","key":"1441_CR26","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1191\/1478088706qp063oa","volume":"3","author":"V Braun","year":"2006","unstructured":"Braun V, Clarke V. Using thematic analysis in psychology. Qual Res Psychol. 2006;3(2):77\u2013101. https:\/\/doi.org\/10.1191\/1478088706qp063oa.","journal-title":"Qual Res Psychol"},{"issue":"6","key":"1441_CR27","doi-asserted-by":"publisher","first-page":"1725","DOI":"10.1016\/j.japh.2022.07.008","volume":"62","author":"RK Lai","year":"2022","unstructured":"Lai RK, Friedson KE, Reveles KR, et al. Naloxone accessibility without an outside prescription from U.S. community pharmacies: a systematic review. J Am Pharm Assoc. 2022;62(6):1725\u201340. https:\/\/doi.org\/10.1016\/j.japh.2022.07.008.","journal-title":"J Am Pharm Assoc"},{"issue":"4","key":"1441_CR28","doi-asserted-by":"publisher","first-page":"457","DOI":"10.5811\/WESTJEM.17979","volume":"25","author":"P Quincy Moore","year":"2024","unstructured":"Quincy Moore P, Ellis K, Simmer P, et al. Accessibility of Naloxone in pharmacies registered under the Illinois standing order. West J Emerg Med. 2024;25(4):457\u201364. https:\/\/doi.org\/10.5811\/WESTJEM.17979.","journal-title":"West J Emerg Med"},{"key":"1441_CR29","doi-asserted-by":"publisher","DOI":"10.1186\/s12954-025-01268-y","volume":"22","author":"K Hill","year":"2025","unstructured":"Hill K, Canning P, Canning Z, et al. Community-originated research to identify access gaps in over-the-counter naloxone availability in Connecticut pharmacies. Harm Reduct J. 2025;22:119. https:\/\/doi.org\/10.1186\/s12954-025-01268-y.","journal-title":"Harm Reduct J"},{"key":"1441_CR30","unstructured":"Texas Health Data - Naloxone Distribution Interactive Map. https:\/\/healthdata.dshs.texas.gov\/dashboard\/drugs-and-alcohol\/all-drugs\/naloxone-distribution-interactive-map. Accessed 5 Feb 2026"},{"issue":"5","key":"1441_CR31","doi-asserted-by":"publisher","DOI":"10.1001\/JAMANETWORKOPEN.2023.16089","volume":"6","author":"SG Weiner","year":"2023","unstructured":"Weiner SG, Qato DM, Faust JS, Clear B. Pharmacy availability of buprenorphine for opioid use disorder treatment in the US. JAMA Netw Open. 2023;6(5):e2316089-e2316089. https:\/\/doi.org\/10.1001\/JAMANETWORKOPEN.2023.16089.","journal-title":"JAMA Netw Open"},{"issue":"8","key":"1441_CR32","doi-asserted-by":"publisher","DOI":"10.1001\/JAMAHEALTHFORUM.2022.2839","volume":"3","author":"DM Qato","year":"2022","unstructured":"Qato DM, Watanabe JH, Clark KJ. Federal and state pharmacy regulations and dispensing barriers to buprenorphine access at retail pharmacies in the US. JAMA Health Forum. 2022;3(8):e222839-e222839. https:\/\/doi.org\/10.1001\/JAMAHEALTHFORUM.2022.2839.","journal-title":"JAMA Health Forum"},{"issue":"4","key":"1441_CR33","doi-asserted-by":"publisher","first-page":"272","DOI":"10.1097\/ADM.0000000000000762","volume":"15","author":"B Ostrach","year":"2021","unstructured":"Ostrach B, Carpenter D, Cote LP. DEA disconnect leads to buprenorphine bottlenecks. J Addict Med. 2021;15(4):272\u20135. https:\/\/doi.org\/10.1097\/ADM.0000000000000762.","journal-title":"J Addict Med"},{"key":"1441_CR34","doi-asserted-by":"publisher","DOI":"10.1016\/J.DRUGPO.2020.102701","author":"HL Cooper","year":"2020","unstructured":"Cooper HL, Cloud DH, Freeman PR, et al. Buprenorphine dispensing in an epicenter of the U.S. opioid epidemic: a case study of the rural risk environment in Appalachian Kentucky. Int J Drug Policy. 2020. https:\/\/doi.org\/10.1016\/J.DRUGPO.2020.102701.","journal-title":"Int J Drug Policy"},{"issue":"5","key":"1441_CR35","doi-asserted-by":"publisher","first-page":"1606","DOI":"10.1016\/J.JAPH.2022.04.019","volume":"62","author":"D Carpenter","year":"2022","unstructured":"Carpenter D, Lambert KV, Harless JC, et al. North Carolina community pharmacists\u2019 buprenorphine dispensing practices and attitudes. J Am Pharm Assoc. 2022;62(5):1606\u201314. https:\/\/doi.org\/10.1016\/J.JAPH.2022.04.019.","journal-title":"J Am Pharm Assoc"},{"issue":"14","key":"1441_CR36","doi-asserted-by":"publisher","first-page":"2055","DOI":"10.1080\/10826084.2024.2392545","volume":"59","author":"SI Sitar","year":"2024","unstructured":"Sitar SI, Yarbrough CR, Mataczynski MJ, et al. Qualitative assessment of barriers to buprenorphine access: the role of pharmacies. Subst Use Misuse. 2024;59(14):2055\u201363. https:\/\/doi.org\/10.1080\/10826084.2024.2392545.","journal-title":"Subst Use Misuse"},{"issue":"1","key":"1441_CR37","doi-asserted-by":"publisher","first-page":"252","DOI":"10.1016\/J.JAPH.2022.08.017","volume":"63","author":"LG Hill","year":"2023","unstructured":"Hill LG, Light AE, Green TC, Burns AL, Sanaty Zadeh P, Freeman PR. Perceptions, policies, and practices related to dispensing buprenorphine for opioid use disorder: a national survey of community-based pharmacists. J Am Pharm Assoc. 2023;63(1):252-260.e6. https:\/\/doi.org\/10.1016\/J.JAPH.2022.08.017.","journal-title":"J Am Pharm Assoc"},{"issue":"4","key":"1441_CR38","doi-asserted-by":"publisher","DOI":"10.1001\/JAMAHEALTHFORUM.2025.0142","volume":"6","author":"PA Abraham","year":"2025","unstructured":"Abraham PA, Kannarkat JT, Qato DM. Reforming markets to strengthen independent pharmacies. JAMA Health Forum. 2025;6(4):e250142-e250142. https:\/\/doi.org\/10.1001\/JAMAHEALTHFORUM.2025.0142.","journal-title":"JAMA Health Forum"},{"issue":"6","key":"1441_CR39","doi-asserted-by":"publisher","first-page":"727","DOI":"10.1331\/JAPHA.2011.10099","volume":"51","author":"MB Carr","year":"2011","unstructured":"Carr MB, Divine H, Hanna C, Freeman PR, Blumenschein K. Independent community pharmacist interest in participating in community pharmacy research networks. J Am Pharm Assoc. 2011;51(6):727\u201338. https:\/\/doi.org\/10.1331\/JAPHA.2011.10099.","journal-title":"J Am Pharm Assoc"},{"issue":"6","key":"1441_CR40","doi-asserted-by":"publisher","first-page":"649","DOI":"10.1331\/JAPHA.2015.14244","volume":"55","author":"P Patel","year":"2015","unstructured":"Patel P, Hemmeger H, Kozak MA, Gernant SA, Snyder ME. Community pharmacist participation in a practice-based research network: a report from the Medication Safety Research Network of Indiana (Rx-SafeNet). J Am Pharm Assoc. 2015;55(6):649\u201355. https:\/\/doi.org\/10.1331\/JAPHA.2015.14244.","journal-title":"J Am Pharm Assoc"}],"container-title":["Harm Reduction Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12954-026-01441-x","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12954-026-01441-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12954-026-01441-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,13]],"date-time":"2026-05-13T08:17:43Z","timestamp":1778660263000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12954-026-01441-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,2]]},"references-count":40,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["1441"],"URL":"https:\/\/doi.org\/10.1186\/s12954-026-01441-x","relation":{},"ISSN":["1477-7517"],"issn-type":[{"value":"1477-7517","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,2]]},"assertion":[{"value":"28 October 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 March 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 April 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was deemed exempt by the University of Texas Medical Branch Institutional Review Board as classified as a quality improvement initiative and not human subjects research.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"This manuscript does not contain any individual person\u2019s data in any form (including details, images, or videos).","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"86"}}